Business
Eloxx Pharmaceuticals Announces that Two Abstracts for ELX-02 Have Been Accepted for Presentation at the 41st European Cystic Fibrosis Conference
Eloxx Pharmaceuticals Announces that Two Abstracts for ELX-02 Have Been Accepted for Presentation at the 41st European Cystic Fibrosis Conference.
About this update from Eloxx Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n ELX-02 is an investigational, novel translational read-through inducing drug designed to restore synthesis of full-length functional proteins\n Late Breaker evaluation of ELX-02 in cystic fibrosis patient organoids with nonsense mutations Eloxx expects to initiate a Phase 2 clinical trial for ELX-02 in cystic fibrosis by the end of 2018, subject to regulatory review and clearance of our CTA WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELX:OTCQ), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that two abstracts, including one Later Breaker, for its lead candidate, ELX-02 will be presented at the 41st European Cystic Fibrosis Conference taking place on June 6-9, 2018 in Belgrade, Serbia. “We are pleased to have this opportunity to present new data for ELX-02 in organoids from cystic fibrosis patients with nonsense mutations to the scientific community. These patients have a high burden of disease, and few, if any, treatment options available,” said Dr. Pedro Huertas, Chief Medical Officer of Eloxx Pharmaceuticals. “We plan to initiate a Phase 2 clinical trial in cystic fibrosis patients with nonsense mutations by the end of this year, subject to regulatory clearance of our CTA in Belgium. We are committed to bringing forward therapeutic options which have the potential to transform lives.’” The details for the two oral ELX-02 presentations are: Oral Presentation Title: “Translational read-through of CFTR nonsense mutations and inducement of cystic fibrosis transmembrane conductance regulator (CFTR) function by ELX-02”Presenter: Neal Sharpe, Ph.D., Senior Director, Preclinical Safety, R & D, Eloxx Pharmaceuticals Time: Thursday, June 7, 2018 from 3:30 pm - 3:45 pm CET, or 9:30 am – 9:45 am ET Oral Late Breaker Presentation Title: “Evaluation of ELX-02 in Cystic Fibrosis Organoids with Non-Sense Mutations”Presenter: Dr. Pedro Huertas, Chief Medical Officer, Eloxx PharmaceuticalsTime: Friday, June 8, 2018 from 5:00 pm - 5:30 pm CET, or 11:00 am - 11:30 pm ET Listen to a Discussion with the HUB We hosted a c...